# IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

> **NCT07361874** · NA · RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 75 (estimated)

## Conditions studied

- Mild Autonomous Cortisol Secretion (MACS)
- Autonomous Cortisol Secretion (ACS)
- Subclinical Cushing's
- Mild Autonomous Cortisol Excess

## Interventions

- **PROCEDURE:** Intervention 1: Adrenalectomy
- **DRUG:** Intervention 2: Semaglutide

## Key facts

- **NCT ID:** NCT07361874
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2030-05-31
- **Final completion:** 2030-05-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07361874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07361874, "IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07361874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*